- Home
- ZH vs BDTX Comparison
ZH vs BDTX Comparison
Compare ZH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZH | BDTX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.7M | 116.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZH | BDTX |
|---|---|---|
| Price | $2.59 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 358.7K | ★ 571.5K |
| Earning Date | 03-25-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.74 | ★ $5.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.68 | $1.20 |
| 52 Week High | $5.55 | $4.94 |
Technical Indicators
Market Signals| Indicator | ZH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 40.78 |
| Support Level | N/A | $1.93 |
| Resistance Level | $4.53 | $2.30 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 5.43 | 11.54 |
Price Performance
Historical ComparisonAbout ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.